Fungal biodegradation of chlorinated herbicides: an overview with an emphasis on 2,4-D in Argentina.

Chlorinated herbicides are one of the main types of pesticide used in agriculture. In Argentina, 2,4-dichlorophenoxyacetic acid (2,4-D) is the most applied herbicide for the control of broadleaf weeds, but the risks it poses for the environment and human health are cause for great concern. A promising technology to remove this kind of pollutants, or neutralize them in such a way that they become less or non-toxic, is the use of degrading or detoxifying microorganisms from contaminated sites. Filamentous fungi can bioremediate xenobiotics thanks to their efficient enzymatic machinery. However, most studies on the degradation of 2,4-D have been carried out with bacteria, and little is known about whether it can be efficiently biodegraded by fungi. In the environment, fungal strains and native microbiota may detoxify contaminants through mechanisms like biosorption, bioabsortion, biotransformation, and/or degradation. Whether these processes occur separately or simultaneously depends on the metabolic ability of the strains that conform the microbial community. Another important concern when attempting to introduce detoxifying microorganisms into a contaminated environment is the GRAS ("Generally Recognized As Safe") assessment or status. These are studies that help predict a biodegrading microorganism's pathogenicity, toxicity, and infectivity before in situ application. This application, moreover, is regulated by different legal frameworks. The present review aims to outline the main aspects of 2,4-D degradation by fungi, and to summarize the current state of research on the topic in Argentina.

CRISPR/Cas- and Topical RNAi-Based Technologies for Crop Management and Improvement: Reviewing the Risk Assessment and Challenges Towards a More Sustainable Agriculture.

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated gene (Cas) system and RNA interference (RNAi)-based non-transgenic approaches are powerful technologies capable of revolutionizing plant research and breeding. In recent years, the use of these modern technologies has been explored in various sectors of agriculture, introducing or improving important agronomic traits in plant crops, such as increased yield, nutritional quality, abiotic- and, mostly, biotic-stress resistance. However, the limitations of each technique, public perception, and regulatory aspects are hindering its wide adoption for the development of new crop varieties or products. In an attempt to reverse these mishaps, scientists have been researching alternatives to increase the specificity, uptake, and stability of the CRISPR and RNAi system components in the target organism, as well as to reduce the chance of toxicity in nontarget organisms to minimize environmental risk, health problems, and regulatory issues. In this review, we discuss several aspects related to risk assessment, toxicity, and advances in the use of CRISPR/Cas and topical RNAi-based technologies in crop management and breeding. The present study also highlights the advantages and possible drawbacks of each technology, provides a brief overview of how to circumvent the off-target occurrence, the strategies to increase on-target specificity, the harm/benefits of association with nanotechnology, the public perception of the available techniques, worldwide regulatory frameworks regarding topical RNAi and CRISPR technologies, and, lastly, presents successful case studies of biotechnological solutions derived from both technologies, raising potential challenges to reach the market and being social and environmentally safe.

The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.

Nanomedicine plays an essential role in developing new therapies through novel drug delivery systems, diagnostic and imaging systems, vaccine development, antibacterial tools, and high-throughput screening. One of the most promising drug delivery systems are nanoparticles, which can be designed with various compositions, sizes, shapes, and surface modifications. These nanosystems have improved therapeutic profiles, increased bioavailability, and reduced the toxicity of the product they carry. However, the clinical translation of nanomedicines requires a thorough understanding of their properties to avoid problems with the most questioned aspect of nanosystems: safety. The particular physicochemical properties of nano-drugs lead to the need for additional safety, quality, and efficacy testing. Consequently, challenges arise during the physicochemical characterization, the production process, in vitro characterization, in vivo characterization, and the clinical stages of development of these biopharmaceuticals. The lack of a specific regulatory framework for nanoformulations has caused significant gaps in the requirements needed to be successful during their approval, especially with tests that demonstrate their safety and efficacy. Researchers face many difficulties in establishing evidence to extrapolate results from one level of development to another, for example, from an in vitro demonstration phase to an in vivo demonstration phase. Additional guidance is required to cover the particularities of this type of product, as some challenges in the regulatory framework do not allow for an accurate assessment of NPs with sufficient evidence of clinical success. This work aims to identify current regulatory issues during the implementation of nanoparticle assays and describe the major challenges that researchers have faced when exposing a new formulation. We further reflect on the current regulatory standards required for the approval of these biopharmaceuticals and the requirements demanded by the regulatory agencies. Our work will provide helpful information to improve the success of nanomedicines by compiling the challenges described in the literature that support the development of this novel encapsulation system. We propose a step-by-step approach through the different stages of the development of nanoformulations, from their design to the clinical stage, exemplifying the different challenges and the measures taken by the regulatory agencies to respond to these challenges.

Microemulsion systems: from the design and architecture to the building of a new delivery system for multiple-route drug delivery.

Poorly soluble active pharmaceutical ingredients (APIs) create major problems in drug dosage form formulation resulting in significant delays in drug pharmaceutical screening, impairing the drug dosage form production. Aiming to minimize the use of excipients for increasing drug apparent solubility and, as a result, its bioavailability, exploration of innovative approaches is an earnest need. Microemulsion is an alternative drug delivery system that emerged as a valuable tool to achieve safe formulations for insoluble compounds and to improve their biopharmaceutical properties and pharmacokinetics. This review aims to present the state of the art of microemulsion systems, bringing an overview about their origin and how they can be properly produced and thoroughly characterized by different approaches. Furthermore, comments on regulatory issues regarding stability assessment and toxicity evaluation are discussed. The review concludes with a current opinion on microemulsion systems. The overall objective of this work was to describe all the potentialities of microemulsion systems as a drug carrier for therapeutic purposes, highlighting the unique features of this nanotechnological platform. Display Image.

Innovación: consideraciones regulatorias de las vacunas de ADN / Innovation: Regulatory considerations for DNA vaccines

Las nuevas vacunas profilácticas de ADN son vacunas que se basan en la introducción de ácidos nucleicos en el organismo del huésped a inmunizar, donde dirigen la síntesis de un péptido que luego será capaz de producir una respuesta inmune protectora tanto humoral como celular. Este tipo de vacunas está diseñado para permitir una expresión localizada y breve del antígeno en cuestión y sin integración del material genético. La técnica involucra el uso de plásmidos de ADN que están conformados por un cassette de expresión codificando el/los antígenos de interés (provenientes de virus, bacterias o parásitos). Existen en la actualidad ensayos clínicos activos que evalúan la seguridad y eficacia de las vacunas de ADN tanto terapéuticas como profilácticas, siendo algunas candidatas que han avanzado hacia la fase II. La regulación de este tipo de vacunas, presenta un desafío regulatorio para las autoridades competentes en todo el mundo. Si bien existen guías para su evaluación aún se requieren estudios exhaustivos para la aprobación y uso de las mismas debido a la complejidad que presentan. La disposición vigente en Argentina contempla los requerimientos generales para este tipo de vacunas, sin embargo a futuro sería conveniente establecer nuevos lineamientos específicos para las vacunas de ADN

The new prophylactic DNA vaccines are based on the introduction of nucleic acids into the host to be immunized, in which they induce the synthesis of a peptide that can produce a protective humoral and cellular immune response. This type of vaccine is designed to allow a localized and brief expression of the antigen without genetic material integration. The technique involves the use of plasmid DNA containing an expression cassette that codifies the antigen of interest (associated to viruses, bacteria or parasites). There are many clinical assays that are evaluating safety and efficacy of prophylactic and therapeutic DNA vaccines; some of them have reached phase II trials. The regulation of this kind of vaccines represents a regulatory challenge for the competent authorities worldwide. Even though there are many guides to evaluate them, exhaustive research is still required for their approval and use due to their complexity. The current provision in Argentina considers the general requirements for this type of vaccines, however, in the future it would be advisable to establish new specific guidelines for DNA vaccines.

Approaches to empower the implementation of new tools to detect and prevent foodborne pathogens in food processing.

Foodborne pathogens cause an important public health burden, which is estimated in 600 million cases and more than 400,000 deaths, globally every year. The most susceptible populations, such as children under the age of five, the elderly and immunocompromised, account for the majority of the deaths. Food safety incidents, outbreaks, sporadic cases, and recalls have recognized economic impact, estimated at 7 billion every year in the US. Food safety has become a priority, and the implementation of preventive controls and monitoring systems has raised the development of new tools to detect and prevent pathogens in the food chain. Detection tools have evolved quickly, from rapid testing methods to application of genomics and metagenomics. Importantly, to reduce food safety hazards at food processing, the food chain needs to be seen from farm to fork. This review summarized the main findings discussed during the 2016 OECD-sponsored symposium on food safety. These include i) trends in food safety that embrace the need to implement new tools in detection and prevention, ii) the very rapid evolution of technologies to detect foodborne pathogens, iii) holistic approaches to prevent pathogens require a whole chain approach, and iv) key pillars to facilitate global implementations of new tools in food safety.

Tumor banking for health research in Brazil and Latin America: time to leave the cradle

Cancer is rapidly growing to be one of the major health burdens in Brazil and Latin America. Access to tumor samples is one of the many barriers that need to be removed in order to promote clinical and translational research aimed at developing and improving cancer prevention and treatment in this region. Although there is a growing interest in establishing tumor collections in many hospitals and institutions, success is limited by the lack of knowledge of the complexities of this activity. This article reviews the regulatory, pathology, and molecular aspects that are relevant to the establishment of tumor banks in Brazil and Latin America. It also provides an overview of key players in the region (AU)